Advertisement

Main pancreatic duct dilation greater than 6 mm is associated with an increased risk of high-grade dysplasia and cancer in IPMN patients

  • Zeeshan Ateeb
  • Roberto Valente
  • Raffaella M. Pozzi-Mucelli
  • Linnéa Malgerud
  • Yasmine Schlieper
  • Elena Rangelova
  • Carlos Fernandez-Moro
  • Johannes Matthias Löhr
  • Urban Arnelo
  • Marco Del ChiaroEmail author
ORIGINAL ARTICLE
  • 52 Downloads

Abstract

Introduction

IPMNs, considered precursor lesions of pancreatic adenocarcinoma (PDAC), might display histological alteration varying from low-grade dysplasia (LGD) to cancer. Nevertheless, the prevalence of PDAC is far below the prevalence of IPMN; therefore, not all of these precursor lesions finally progress to cancer. Preoperative features consistent with and finding at final histology of high-grade dysplasia (HGD) or cancer are currently lacking. The aim of this study is to correlate the presence of preoperative clinical features with the finding of advance lesions at final histology.

Methods

This is retrospective cohort analysis of patients who underwent surgery for histologically confirmed IPMNs at Karolinska University Hospital, from 2008 to 2015.

Results

MPD 6–9.9 mm and ≥ 10 mm were associated with an increased risk of HGD/cancer (respectively, OR 2.92, CI 1.38–6.20, p = 0.005 and OR 2.65, CI 1.12–6.25, p = 0.02). Preoperative high CA19.9 and jaundice were both associated with a higher risk of HGD/cancer at final histology (respectively, OR 4.15, CI 1.90–9.05, p = 0.0003 and OR 15.36, CI 1.94–121.22, p = 0.009). At sex- and age-adjusted multivariable logistic regression analysis, MPD between 6 and 9.9 mm (OR 2.64, CI 1.15–6.06, p = 0.02), jaundice (OR 12.43, CI 1.44–106.93, p = 0.02), and elevated CA19.9 (OR 3.71, CI 1.63–8.46, p = 0.001) remained associated with the occurrence of HGD/cancer.

Discussion

The presence of MPD dilation ≥ 6 mm, jaundice, and elevated CA19.9 in IPMN patients are consistent with the finding for HGD/cancer at final histology, thus representing possible markers of advanced lesions suitable for earlier or preventive curative surgical treatment.

Keywords

Intraductal papillary mucinous neoplasms of the pancreas (IPMN) Pancreas cancer prevention Early diagnosis Pancreas surgery Pancreatic cystic tumors 

Notes

Author’s contributions

Zeeshan Ateeb collected the data and contributed to write the manuscript. Roberto Valente contributed to write the manuscript and performed the statistical analysis. Yasmine Schlieper contributed to collect data. Carlos Fernaned Moro revised the patient’s histology. Raffaella M. Pozzi-Mucelli revised the patient’s radiological files. Linnea Malgerud, Elena Rangelova, Johannes Matthias Löhr, and Urban Arnelo critically revised the manuscript. Marco Del Chiaro was responsible of the study design and contributed to write the paper.

Funding

The present study was supported by Cancerfonden, Sweden (CAN 2014/634 and CAN 2014/621) and ALF Medicine (2016 #20150113).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Ethical approval was obtained by the local ethical committee (EPN 2015/1544–31/4).

References

  1. 1.
    Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913–2921CrossRefGoogle Scholar
  2. 2.
    Lohr JM (2014) Pancreatic cancer should be treated as a medical emergency. BMJ g5261:349Google Scholar
  3. 3.
    Del Chiaro M, Segersvard R, Lohr M, Verbeke C (2014) Early detection and prevention of pancreatic cancer: is it really possible today? World J Gastroenterol 20(34):12118–12131CrossRefGoogle Scholar
  4. 4.
    Del Chiaro M, Verbeke C (2017) Intraductal papillary mucinous neoplasms of the pancreas: reporting clinically relevant features. Histopathology 70(6):850–860CrossRefGoogle Scholar
  5. 5.
    Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S et al (2008) Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol 191(3):802–807CrossRefGoogle Scholar
  6. 6.
    Zhang XM, Mitchell DG, Dohke M, Holland GA, Parker L (2002) Pancreatic cysts: depiction on single-shot fast spin-echo MR images. Radiology 223(2):547–553CrossRefGoogle Scholar
  7. 7.
    Del Chiaro M, Segersvard R, Pozzi Mucelli R, Rangelova E, Kartalis N, Ansorge C et al (2014) Comparison of preoperative conference-based diagnosis with histology of cystic tumors of the pancreas. Ann Surg Oncol 21(5):1539–1544CrossRefGoogle Scholar
  8. 8.
    Del Chiaro M, Verbeke CS, Kartalis N, Pozzi Mucelli R, Gustafsson P, Hansson J et al (2015) Short-term results of a magnetic resonance imaging-based Swedish screening program for individuals at risk for pancreatic Cancer. JAMA Surg 150(6):512–518CrossRefGoogle Scholar
  9. 9.
    Del Chiaro M, Verbeke C, Salvia R, Kloppel G, Werner J, McKay C et al (2013) European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis 45(9):703–711CrossRefGoogle Scholar
  10. 10.
    Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY et al (2012) International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12(3):183–197CrossRefGoogle Scholar
  11. 11.
    Vege SS, Ziring B, Jain R, Moayyedi P (2015) American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 148(4):819–822 quize12–3CrossRefGoogle Scholar
  12. 12.
    Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T et al (2017) Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17(5):738–753CrossRefGoogle Scholar
  13. 13.
    Hackert T, Fritz S, Klauss M, Bergmann F, Hinz U, Strobel O et al (2015) Main-duct intraductal papillary mucinous neoplasm: high cancer risk in duct diameter of 5 to 9 mm. Ann Surg 262(5):875–881CrossRefGoogle Scholar
  14. 14.
    Del Chiaro M, Schulick RD (2016) Main-duct intraductal papillary mucinous neoplasm. High cancer risk in duct diameter of 5 to 9 mm. Ann SurgGoogle Scholar
  15. 15.
    Sugimoto M, Elliott IA, Nguyen AH, Kim S, Muthusamy VR, Watson R et al (2017) Assessment of a revised management strategy for patients with Intraductal papillary mucinous neoplasms involving the Main pancreatic duct. JAMA Surg 152(1):e163349CrossRefGoogle Scholar
  16. 16.
    Fritz S, Hackert T, Hinz U, Hartwig W, Buchler MW, Werner J (2011) Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg 98(1):104–110CrossRefGoogle Scholar
  17. 17.
    Brennan MF (2003) Presumption, privilege, and preemption. Ann Surg 238(3):307–314PubMedPubMedCentralGoogle Scholar
  18. 18.
    Del Chiaro M, Ateeb Z, Hansson MR, Rangelova E, Segersvard R, Kartalis N et al (2017) Survival analysis and risk for progression of Intraductal papillary mucinous neoplasia of the pancreas (IPMN) under surveillance: a single-institution experience. Ann Surg Oncol 24(4):1120–1126CrossRefGoogle Scholar
  19. 19.
    Correa-Gallego C, Ferrone CR, Thayer SP, Wargo JA, Warshaw AL, Fernandez-Del CC (2010) Incidental pancreatic cysts: do we really know what we are watching? Pancreatology 10(2–3):144–150CrossRefGoogle Scholar
  20. 20.
    Salvia R, Malleo G, Marchegiani G, Pennacchio S, Paiella S, Paini M et al (2012) Pancreatic resections for cystic neoplasms: from the surgeon's presumption to the pathologist's reality. Surgery 152(3 Suppl 1):S135–S142CrossRefGoogle Scholar
  21. 21.
    Jais B, Rebours V, Malleo G, Salvia R, Fontana M, Maggino L et al (2016) Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European study group on cystic tumors of the pancreas). Gut 65(2):305–312CrossRefGoogle Scholar
  22. 22.
    Macedo FIB, Jayanthi P, Mowzoon M, Yakoub D, Dudeja V, Merchant N (2017) The impact of surgeon volume on outcomes after Pancreaticoduodenectomy: a meta-analysis. J Gastrointest SurgGoogle Scholar
  23. 23.
    Lucas AL, Malvezzi M, Carioli G, Negri E, La Vecchia C, Boffetta P et al (2016) Global Trends in Pancreatic Cancer Mortality From 1980 Through 2013 and Predictions for 2017. Clin Gastroenterol Hepatol 14(10):1452–62.e4CrossRefGoogle Scholar
  24. 24.
    Kamata K, Kitano M. Endoscopic diagnosis of cystic lesions of the pancreas. 2018CrossRefGoogle Scholar
  25. 25.
    Fritz S, Klauss M, Bergmann F, Hackert T, Hartwig W, Strobel O et al (2012) Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg 256(2):313–320CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Zeeshan Ateeb
    • 1
  • Roberto Valente
    • 1
    • 2
  • Raffaella M. Pozzi-Mucelli
    • 3
  • Linnéa Malgerud
    • 1
  • Yasmine Schlieper
    • 1
  • Elena Rangelova
    • 1
  • Carlos Fernandez-Moro
    • 4
  • Johannes Matthias Löhr
    • 1
  • Urban Arnelo
    • 1
  • Marco Del Chiaro
    • 1
    • 5
  1. 1.Pancreatic Surgery Unit, Division of Surgery, Department of Clinical Science, Intervention, and TechnologyKarolinska InstitutetStockholmSweden
  2. 2.Digestive and Liver Diseases UnitSapienza University of RomeRomeItaly
  3. 3.Division of Radiology, Department of Clinical Science, Intervention, and TechnologyKarolinska InstitutetStockholmSweden
  4. 4.Division of Pathology, Department of Laboratory MedicineKarolinska InstitutetStockholmSweden
  5. 5.Division of Surgical Oncology, Department of SurgeryUniversity of Colorado Anschutz Medical CampusAuroraUSA

Personalised recommendations